Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib

Paul J. Hampel; Hua Jay J. Cherng; Timothy G. Call; Wei Ding; Mahsa Khanlari; Ellen D. McPhail; Roberto N. Miranda; Pei Lin; Hussein A. Tawbi; Alessandra Ferrajoli; William G. Wierda; Nitin Jain; Sameer A. Parikh

doi:10.1182/BLOODADVANCES.2020002454

Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib

Paul J. Hampel, Hua Jay J. Cherng, Timothy G. Call, Wei Ding, Mahsa Khanlari, Ellen D. McPhail, Roberto N. Miranda, Pei Lin, Hussein A. Tawbi, Alessandra Ferrajoli, William G. Wierda, Nitin Jain, Sameer A. Parikh

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	4508-4511
Number of pages	4
Journal	Blood Advances
Volume	4
Issue number	18
DOIs	https://doi.org/10.1182/BLOODADVANCES.2020002454
State	Published - Sep 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/BLOODADVANCES.2020002454

Cite this

Hampel, P. J., Cherng, H. J. J., Call, T. G., Ding, W., Khanlari, M., McPhail, E. D., Miranda, R. N., Lin, P., Tawbi, H. A., Ferrajoli, A., Wierda, W. G., Jain, N., & Parikh, S. A. (2020). Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Advances, 4(18), 4508-4511. https://doi.org/10.1182/BLOODADVANCES.2020002454

Hampel, PJ, Cherng, HJJ, Call, TG, Ding, W, Khanlari, M, McPhail, ED, Miranda, RN, Lin, P, Tawbi, HA, Ferrajoli, A, Wierda, WG, Jain, N & Parikh, SA 2020, 'Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib', Blood Advances, vol. 4, no. 18, pp. 4508-4511. https://doi.org/10.1182/BLOODADVANCES.2020002454

@article{0243bed27356411e9bdc581f3e784a7d,

title = "Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib",

author = "Hampel, {Paul J.} and Cherng, {Hua Jay J.} and Call, {Timothy G.} and Wei Ding and Mahsa Khanlari and McPhail, {Ellen D.} and Miranda, {Roberto N.} and Pei Lin and Tawbi, {Hussein A.} and Alessandra Ferrajoli and Wierda, {William G.} and Nitin Jain and Parikh, {Sameer A.}",

note = "Funding Information: grants from Bristol-Myers Squibb, Merck & Co., Genentech, GlaxoSmithKline, and Celgene. A.F. reports research funding Celgene, Acerta, Beigene. W.G.W. reports grants from AbbVie, GlaxoSmithKline, Novartis, Genentech, Pharmacyclics, Gilead, Acerta, JUNO (Celegene), KITE Pharma (Gilead), Sunesis, Miragen, Oncturnal Therapeutics, LOXO Oncology, Cyclacel, Janssen, and Xencor, and nonfinancial support from AbbVie, Genentech, Pharmacyclics, Gilead, Acerta, JUNO (Celgene), KITE Pharma (Gilead), Sunesis, Oncturnal Therapeutics, LOXO Oncology, and Janssen outside the submitted work. N.J. reports research funding has been provided to the institution from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Verastem, Adaptive Biotechnologies, and Precision Biosciences for clinical studies in which N.J. is a principal investigator, and has participated in advisory board meetings and received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Verastem, Adaptive Biotechnologies,",

year = "2020",

month = sep,

doi = "10.1182/BLOODADVANCES.2020002454",

language = "English (US)",

volume = "4",

pages = "4508--4511",

journal = "Blood advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "18",

}

TY - JOUR

T1 - Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib

AU - Hampel, Paul J.

AU - Cherng, Hua Jay J.

AU - Call, Timothy G.

AU - Ding, Wei

AU - Khanlari, Mahsa

AU - McPhail, Ellen D.

AU - Miranda, Roberto N.

AU - Lin, Pei

AU - Tawbi, Hussein A.

AU - Ferrajoli, Alessandra

AU - Wierda, William G.

AU - Jain, Nitin

AU - Parikh, Sameer A.

N1 - Funding Information: grants from Bristol-Myers Squibb, Merck & Co., Genentech, GlaxoSmithKline, and Celgene. A.F. reports research funding Celgene, Acerta, Beigene. W.G.W. reports grants from AbbVie, GlaxoSmithKline, Novartis, Genentech, Pharmacyclics, Gilead, Acerta, JUNO (Celegene), KITE Pharma (Gilead), Sunesis, Miragen, Oncturnal Therapeutics, LOXO Oncology, Cyclacel, Janssen, and Xencor, and nonfinancial support from AbbVie, Genentech, Pharmacyclics, Gilead, Acerta, JUNO (Celgene), KITE Pharma (Gilead), Sunesis, Oncturnal Therapeutics, LOXO Oncology, and Janssen outside the submitted work. N.J. reports research funding has been provided to the institution from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Verastem, Adaptive Biotechnologies, and Precision Biosciences for clinical studies in which N.J. is a principal investigator, and has participated in advisory board meetings and received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Verastem, Adaptive Biotechnologies,

PY - 2020/9

Y1 - 2020/9

UR - http://www.scopus.com/inward/record.url?scp=85092225522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092225522&partnerID=8YFLogxK

U2 - 10.1182/BLOODADVANCES.2020002454

DO - 10.1182/BLOODADVANCES.2020002454

M3 - Article

C2 - 32946567

AN - SCOPUS:85092225522

SN - 2473-9529

VL - 4

SP - 4508

EP - 4511

JO - Blood advances

JF - Blood advances

IS - 18

ER -

Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this